Clinical-stage biotechnology company developing therapies that enhance the immune system to treat cancer
Clinical-stage biotechnology company developing therapies that enhance the immune system to treat cancer. Its pipeline includes evorpacept, a CD47-inhibiting immuno-oncology candidate, and ALX2004, an EGFR-targeted antibody-drug conjugate for EGFR-expressing solid tumors.